RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 66 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 66

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  3. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  4. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  5. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  6. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  7. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  8. Study siteBinzhou Medical University Hospital滨州医学院附属医院YantaiHospital page
  9. Study siteCangzhou Central Hospital沧州市中心医院TianjinHospital page
  10. Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
  11. Study siteFifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
  12. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  13. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  14. Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
  15. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  16. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  17. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  18. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  19. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  20. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  21. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  22. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  23. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  24. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  25. Study siteFirst Hospital of Shanxi Medical University山西医科大学第一医院TaiyuanHospital page
  26. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  27. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  28. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  29. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  30. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  31. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  32. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  33. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  34. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  35. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  36. Study siteJiangmen Central Hospital江门市中心医院JiangmenHospital page
  37. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  38. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  39. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  40. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  41. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  42. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  43. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  44. Study siteSecond Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院ChongqingHospital page
  45. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  46. Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
  47. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  48. Study siteShenzhen People's Hospital深圳市人民医院ShenzhenHospital page
  49. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  50. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  51. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  52. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  53. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  54. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  55. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
  56. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  57. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  58. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  59. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  60. Study siteXinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院)ChongqingHospital page
  61. Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
  62. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  63. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  64. Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page
  65. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page
  66. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07416474, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histopathologically or cytologically confirmed locally advanced or metastatic NSCLC not eligible for curative treatment.

    Inclusion criterion 6

  3. Female participants must be postmenopausal, surgically sterilized, or of childbearing potential with a negative blood pregnancy test within 7 days before the first dose. Female participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate oocytes or breastfeed during this period. Male participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate sperm during this period.

    Inclusion criterion 9

    Prior systemic anti-tumor treatment other than chemotherapy and PD-1/PD-L1 antibodies.

    Exclusion criterion 7

    Toxic reactions from prior anti-tumor treatment have not recovered to grade 0-1 as defined by CTCAE version 6.0.

    Exclusion criterion 13

    Other malignant tumors within 5 years before the start of study drug administration, except for malignant tumors that are expected to be cured after treatment.

    Exclusion criterion 25

    For participants who have used PD-1/L1 inhibitors, prior occurrence of grade 3 or above irAE related to immunotherapy, irAE leading to permanent discontinuation of treatment, grade 2 immune-related cardiotoxicity, or irAE of any grade involving the nervous system or eyes; prior occurrence of adverse events requiring treatment with immunosuppressive drugs other than corticosteroids, or recurrence of adverse events during previous immunotherapy requiring systemic use of corticosteroids again.

    Exclusion criterion 29

  4. ECOG PS score 0 or 1.

    Inclusion criterion 5

  5. At least one measurable lesion outside of the brain according to the RECIST v1.1 criteria.

    Inclusion criterion 10

  6. Histopathologically or cytologically confirmed non-squamous non-small cell lung cancer.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07416474, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in the study and signed the Informed Consent Form (ICF).
  • Be willing to and able to participate in the trial and comply with the follow up procedures;
  • Male or female, aged 18-75 years.
  • Expected survival ≥ 3 months.
  • ECOG PS score 0 or 1.
  • Histopathologically or cytologically confirmed locally advanced or metastatic NSCLC not eligible for curative treatment.
  • No prior systemic anti-tumor treatment for advanced or metastatic squamous NSCLC.
  • Sufficient cardiac, bone marrow, hepatic, renal, and coagulation function.
  • Female participants must be postmenopausal, surgically sterilized, or of childbearing potential with a negative blood pregnancy test within 7 days before the first dose. Female participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate oocytes or breastfeed during this period. Male participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate sperm during this period.
  • At least one measurable lesion outside of the brain according to the RECIST v1.1 criteria.
  • A PD-L1 expression test report that meets the requirements must be provided before enrollment.

Exclusion Criteria:

  • Histopathologically or cytologically confirmed non-squamous non-small cell lung cancer.
  • Squamous NSCLC with known EGFR sensitive mutations and ALK fusions; squamous NSCLC with known driver gene for which first-line approved treatment options exist.
  • Presence of active brain metastases.
  • Imaging at screening shows obvious tumor necrosis and cavitation, and the investigator judges that participation in the study will cause bleeding risk.
  • Chest radiotherapy > 30Gy within 6 months before randomization; palliative local treatment for non-target lesions within 2 weeks before randomization; non-specific immunomodulatory treatment within 2 weeks before randomization; Chinese herbal medicine or proprietary Chinese medicine treatment with anti-tumor indications within 1 week before randomization.
  • History of immunotherapy. Note: For adjuvant/neoadjuvant phases or curative radiotherapy/chemoradiotherapy, PD-L1/PD-1 antibody therapy should be administered only if recurrence or metastasis occurs more than 12 months after the completion of the last medication.
  • Prior systemic anti-tumor treatment other than chemotherapy and PD-1/PD-L1 antibodies.
  • Systemic treatment with corticosteroids or other immunosuppressive drugs within 2 weeks before randomization.
  • Use of any live or attenuated live vaccines within 4 weeks before randomization, or planned during the study.
  • Participation in other clinical trials within 4 weeks before randomization.
  • Major surgery, interventional therapy, or severe trauma within 4 weeks before randomization, or planned major surgery during the study; core needle biopsy or other minor surgery within 7 days before randomization.
  • Participants with history of severe coagulation dysfunction or current intake of anticoagulant drugs.
  • Toxic reactions from prior anti-tumor treatment have not recovered to grade 0-1 as defined by CTCAE version 6.0.
  • Severe acute or chronic infections.
  • Active gastrointestinal bleeding, hemoptysis, peptic ulcer, or hemorrhagic events requiring intervention within 4 weeks before randomization; or presence of severe esophagogastric varices or epistaxis.
  • Severe arterial/venous thrombotic events or cerebrovascular accidents within 6 months before randomization.
  • Active or clinically significant heart disease.
  • Past or current interstitial lung disease, drug-related pneumonia, radiation pneumonitis, severe impairment of lung function, or clinical manifestations or high-risk factors suspected of interstitial lung disease.
  • History of gastrointestinal perforation and/or fistula, history of gastrointestinal obstruction within 6 months before randomization.
  • Presence of systemically diseases that are not stably controlled as judged by the investigator.
  • Active or history of autoimmune diseases with potential for recurrence.
  • Past history of other acquired or congenital immunodeficiency diseases or organ transplantation.
  • Known hypersensitivity or delayed-type hypersensitivity to certain components of the study drug or similar drugs.
  • Presence of symptomatic or intervention-requiring third-space effusions.
  • Other malignant tumors within 5 years before the start of study drug administration, except for malignant tumors that are expected to be cured after treatment.
  • Poor compliance and expected inability to cooperate with the completion of trial procedures.
  • Past or current history of any other diseases, abnormal physical examination findings, or abnormal laboratory examination findings that, in the investigator's judgment, reasonably suggest that the participant has a disease or condition unsuitable for the use of the study drug.
  • Local or systemic diseases not caused by malignant tumors, or diseases or symptoms secondary to tumors.
  • For participants who have used PD-1/L1 inhibitors, prior occurrence of grade 3 or above irAE related to immunotherapy, irAE leading to permanent discontinuation of treatment, grade 2 immune-related cardiotoxicity, or irAE of any grade involving the nervous system or eyes; prior occurrence of adverse events requiring treatment with immunosuppressive drugs other than corticosteroids, or recurrence of adverse events during previous immunotherapy requiring systemic use of corticosteroids again.

Quoted from ClinicalTrials.gov, NCT07416474, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07416474, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07416474